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Abstract: Previously, we reported that vitamin K3 (VK3), but not VK1 or VK2 (=MK-4), 
inhibits the activity of human DNA polymerase γ (pol γ). In this study, we chemically 
synthesized three intermediate compounds between VK2 and VK3, namely MK-3, MK-2 
and MK-1, and investigated the inhibitory effects of all five compounds on the activity of 
mammalian  pols.  Among  these  compounds,  MK-2  was  the  strongest  inhibitor  of 
mammalian pols ʱ, θ and ι, which belong to the B, Y and X families of pols, respectively; 
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whereas VK3 was the strongest inhibitor of human pol γ, an A-family pol. MK-2 potently 
inhibited the activity of all animal species of pol tested, and its inhibitory effect on pol ι 
activity was the strongest with an IC50 value of 24.6 κM. However, MK-2 did not affect the 
activity of plant or prokaryotic pols, or that of other DNA metabolic enzymes such as 
primase of pol ʱ, RNA polymerase, polynucleotide kinase or deoxyribonuclease I. Because 
we previously found a positive relationship between pol ι inhibition and anti-inflammatory 
action,  we  examined  whether  these  compounds  could  inhibit  inflammatory  responses. 
Among  the  five  compounds  tested,  MK-2  caused  the  greatest  reduction  in  
12-O-tetradecanoylphorbol-13-acetate  (TPA)-induced  acute  inflammation  in  mouse  ear.  
In  addition,  in  a  cell  culture  system  using  mouse  macrophages,  MK-2  displayed  the 
strongest  suppression  of  the  production  of  tumor  necrosis  factor  (TNF)-ʱ  induced  by 
lipopolysaccharide  (LPS).  Moreover,  MK-2  was  found  to  inhibit  the  action  of  nuclear 
factor  (NF)-θB.  In  an  in  vivo  mouse  model  of  LPS-evoked  acute  inflammation, 
intraperitoneal injection of MK-2 in mice led to suppression of TNF-ʱ production in serum. 
In conclusion, this study has identified VK2 and VK3 intermediates, such as MK-2, that are 
promising anti-inflammatory candidates. 
Keywords: vitamin K; MK-2; DNA polymerase ι; enzyme inhibitor; anti-inflammation 
 
1. Introduction 
The  human  genome  encodes  at  least  15  DNA  polymerases  (pols)  that  conduct  cellular  DNA 
synthesis [1,2]. Eukaryotic cells contain three replicative pols (ʱ, δ and ε), 1 mitochondrial pol (γ), and 
at least 11 non-replicative pols (β, δ, ε, ζ, η, θ, ι, κ, λ, terminal deoxynucleotidyl transferase (TdT) and 
REV1) [3,4]. Pols have a highly conserved structure, which means that their overall catalytic subunits 
show little variance among species. Enzymes with conserved structures usually perform important 
cellular  functions,  the  maintenance  of  which  provides  evolutionary  advantages.  On  the  basis  of 
sequence homology, eukaryotic pols can be divided into four main families, termed A, B, X and Y [4]. 
Family A includes mitochondrial pol γ, as well as pols ζ and λ. Family B includes three replicative pols 
(ʱ, δ and ε) and pol δ. Family X comprises pols β, ι and κ, as well as TdT; and lastly, family Y 
includes pols ε, η and θ, in addition to REV1. We have been studying selective inhibitors of each pol 
derived from natural products including food materials and nutrients for more than 15 years [5,6]. 
We have found that vitamin K3 (VK3), but not VK1 or VK2, is a potent and specific inhibitor of 
human pol γ [7–10]. 
VK comprises a family of structurally similar, fat-soluble 2-methyl-1,4-naphthoquinones, including 
phylloquinone (VK1), menaquinone (VK2), and menadione (VK3). 1,4-Naphthoquinones form a family 
of compounds characterized by a naphthalene ring that contains two carbonyl moieties at positions 1 
and 4, and that, in the case of VK, is substituted at positions 2 and 3 (Figure 1). All members of the 
VK  family  possess an identical naphthoquinone skeleton with various side chains that distinguish 
them. VK1 and VK2 differ only in the prosthetic group at position 3. VK1 possesses a phytyl group 
(partially  saturated  poly-isoprenoid  group)  at  position  3,  whereas  VK2  possesses  a  repeating Int. J. Mol. Sci. 2011, 12                     
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unsaturated trans-poly-isoprenyl group. The IUPAC-IUB Commission on Biochemical Nomenclature 
abbreviates  VK2  as  ―MK-n‖,  where  ―n‖  signifies  the  number  of  unsaturated  isoprene  units  that 
compose the side chain at the 3-position. The side chain of MK-n can vary in length from C5 (n = 1) to 
C65 (n = 13); for example, menaquinone 4 (MK-4) could also be written as K2(20). MK-4 (=VK2) has 
three isoprene units plus the first saturated group beginning at position 3, totaling four (Figure 1A). 
The  most  common  form  of  VK  in  animals  is  VK2  in  its  MK-4  structure,  which  is  produced  by 
intestinal  bacteria  from  exogenous  naphthoquinones  and  transformed  endogenously  in  our  own 
cells [11].  VK3  possesses  a  much  simpler  structure,  with  no  aliphatic  chain  prosthetic  group  at 
position 3 (Figure 1E). Although VK3 is considered a synthetic analogue, Billeter et al. found that VK1 
can be cleaved to form VK3 by bacteria in the intestine [12]. After absorption, VK3 is thought to 
become alkylated into biologically active isoprenylated VK2 [13]. However, VK3 cannot exert all of 
the functions of natural VK, a finding that is ascribed to its limited transformation into the fat-soluble 
vitamin forms [14,15]. 
Figure  1. Structures of the VK2 and VK3 intermediates. (A) MK-4 (VK2), (B) MK-3, 
(C) MK-2, (D) MK-1, and (E) VK3. 
(A)  (B) 
   
(C)  (D)  (E) 
     
 
In  our  pol  inhibitor  studies,  we  have  found  that  pol  ι-selective  inhibitors,  such  as  curcumin 
derivatives  [16–18],  have  12-O-tetradecanoylphorbol-13-acetate  (TPA)-induced  anti-inflammatory 
activity  [19–21].  Although  tumor  promoters  are  classified  as  compounds  that  promote  tumor 
formation [22],  they  also  cause  inflammation  and  are  commonly  used  as  artificial  inducers  of 
inflammation  in  order  to  screen  for  anti-inflammatory  agents  [23].  Tumor  promoter-induced 
inflammation can be distinguished from acute inflammation, which is exudative and is accompanied 
by fibroblast proliferation and granulation. The tumor promoter TPA is frequently used to search for 
new types of anti-inflammatory compound. TPA not only causes inflammation, but also influences 
mammalian cell growth [24], suggesting that the molecular basis of the inflammation stems from 
pol reactions  related  to  cell  proliferation.  This  relationship,  however,  needs  to  be  investigated 
more closely. 
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In many inflammatory responses, activation of nuclear factor (NF)-θB is the rate-limiting step of the 
inflammatory  mechanism  [25].  The  five  members  of  the  mammalian  NF-θB  family,  namely 
p65 (RelA), RelB, c-Rel, p50/p105 (NF-θB1) and p52/p100 (NF-θB2), exist in unstimulated cells as 
homodimers or heterodimers bound to proteins of the IθB family [26]. The binding of NF-θB to IθB 
prevents NF-θB from translocating to the nucleus, thereby maintaining NF-θB in an inactive state.  
NF-θB  proteins  are  characterized  by  the  presence  of  a  conserved  300-amino-acid  Rel  homology 
domain located in the N-terminus of the protein, and this domain is responsible for dimerization with 
NF-θB, interaction with IθB, and binding to DNA [26]. The translocated NF-θB proteins work as 
transcription  factors  and  regulate  the  expression  of  various  genes  that  encode  proinflammatory 
cytokines such as tumor necrosis factor (TNF)-ʱ and interleukin (IL)-12, which have been shown to 
play important roles in sustained inflammatory responses [27–29]. 
In this study, we focused on compounds that are intermediates between VK2 (MK-4) and VK3, and 
chemically synthesized three such compounds (MK-3, MK-2 and MK-1) as derivatives of VK2 and 
VK3 (Figure 1B–D). We investigated the inhibitory effects of these five compounds on mammalian pol 
activity and inflammatory responses both in vitro and in vivo. We found that some of the VK2 and VK3 
intermediates suppress NF-θB activation induced by lipopolysaccharide (LPS) in mouse macrophage 
cells. Moreover, we also demonstrated that these compounds exert inhibitory effects against TNF-ʱ 
production in an animal model of LPS-induced acute inflammation. The goal of this study is clarified 
whether VK2 and VK3 intermediates could be a potent chemopreventive agent against inflammation. 
2. Results 
2.1. Effect of the VK2 and VK3 Intermediates on Mammalian Pol Activity 
Initially, we investigated the in vitro biochemical action of VK2 (MK-4), VK3 and their chemically 
synthesized derivatives, MK-3, MK-2 and MK-1. The inhibition of four mammalian pols, namely calf 
pol ʱ, human pol γ, human pol θ and human pol ι, by 50 κM of each compound was investigated. 
Pols ʱ, γ, θ and ι were used as representatives of the B, A, Y and X families of pols, respectively [1–3]. 
As shown in Figure 2, MK-3, MK-2 and MK-1, which are intermediates between VK2 and VK3, 
inhibited the activity of mammalian pols ʱ, θ and ι, whereas MK-4 (VK2) had no effect on pol activity. 
VK3  selectively  inhibited  pol  γ  among  the  mammalian  pols  tested.  The  inhibitory  effect  of  these 
compounds on pols ʱ, θ and ι ranked as follows: MK-2 > MK-1 > MK-3 > MK-4 = VK3; and the 
inhibitory effect of these compounds on pol γ ranked as follows: VK3 > MK-1 > MK-2 > MK-3 > MK-4. 
The IC50 values of MK-2 against pols ʱ, γ, θ and ι were 27.6, 68.8, 35.3 and 24.6 κM, respectively. 
When activated DNA (i.e., bovine deoxyribonuclease I-treated DNA) and dNTP were used as the 
DNA  template-primer  and  nucleotide  substrate  instead  of  synthesized  DNA  [poly(dA)/oligo(dT)18 
(A/T = 2/1)] and dTTP, respectively, the inhibitory effects of these compounds did not change (data 
not shown). 
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Figure  2.  Inhibitory  effects  of  the  VK2  and  VK3  intermediates  on  the  activity  of 
mammalian pols. Each compound (50 κM) was incubated with calf pol ʱ (B-family pol), 
human pol γ (A-family pol), human pol θ (Y-family pol) and human pol ι (X-family pol) 
(0.05 units each). Pol activity in the absence of the compound was taken as 100%, and the 
relative activity is shown. Data are shown as the mean ±  SE (n = 3). ** P < 0.01 and 
* P < 0.05 versus controls. 
 
2.2. Effects of MK-2 on Pols and Other DNA Metabolic Enzymes 
Among  the  five  compounds  investigated,  MK-2  displayed  the  strongest  inhibitory  effect  on 
mammalian pols (Figure 2) and was therefore the focus of this section. As described briefly in the 
introduction, we have succeeded in obtaining ten eukaryotic pol species including pols ʱ, β, γ, δ, ε, η, ε, 
θ and ι, and TdT; however, pols δ, ζ, κ and λ, and REV1 are not yet available (Table 1). Currently, 
eukaryotes are thought to express at least 15 species of pols [1,2], and we are still in an era when most 
pols are very difficult to obtain in their purified form in a laboratory. Table 1 shows the inhibitory 
effect (IC50 value) of MK-2 against various pol species including the ten eukaryotic pols that can be 
obtained. This compound inhibited the activity of all of the pols from mammals, and 50% inhibition of 
the  A,  B,  X  and  Y  families  of  pols  was  observed  at  a  dose  of  68.8,  27.6–29.1,  24.6–31.0  and  
35.3–39.0 κM, respectively; therefore, the strength of the inhibitory effect of MK-2 on mammalian pol 
families can be ranked as follows: B-family pols = X-family pols > Y-family pols > A-family pol. 
MK-2 showed the strongest inhibition of pol ι activity among the pols investigated, with an IC50 value 
of 24.6 κM. This compound also suppressed the activity of the animal pols from fish (cherry salmon) 
and insect (fruit fly) at almost the same concentrations as it inhibited the activity of mammalian pols. 
By contrast, MK-2 had no effect on plant (cauliflower) pol ʱ or prokaryotic pols, such as E. coli 
pol I, Taq pol or T4 pol (Table 1). The three-dimensional structures of eukaryotic pols are likely to 
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differ greatly from those of prokaryotic pols. MK-2 did not inhibit the activity of other DNA metabolic 
enzymes,  such  as  calf  primase  pol  ʱ,  T7  RNA  polymerase,  T4  polynucleotide  kinase,  or  bovine 
deoxyribonuclease I. These results suggest that MK-2 may be a selective inhibitor of animal pols, 
especially the B and X families of pols containing pol ι. 
To test whether MK-2 is an intercalating agent that distorts DNA and subsequently inhibits enzyme 
activity, we measured the thermal transition of DNA in the presence or absence of this compound. The 
thermal transition profile of DNA was the same with or without the compound (data not shown). 
Therefore, the inhibition of pols by MK-2 is not due to DNA distortion, but seems to be due to a direct 
effect of this compound on the enzymes themselves. 
Table 1. IC50 values of MK-2 against the activities of various DNA polymerases and other 
DNA metabolic enzymes. 
Enzyme  IC50 Value of MK-2 (μM) 
  Mammalian DNA Polymerases   
A-family DNA polymerase   
Human DNA polymerase γ  68.8 ±  3.4 
B-family DNA polymerase   
Calf DNA polymerase ʱ  27.6 ±  1.6 
Human DNA polymerase δ  29.1 ±  1.8 
Human DNA polymerase ε  28.2 ±  1.6 
X-family DNA polymerase   
Rat DNA polymerase β  31.0 ±  1.8 
Human DNA polymerase ι  24.6 ±  1.4 
Calf Terminal deoxynucleotidyl transferase  29.4 ±  1.7 
Y-family DNA polymerase   
Human DNA polymerase ε  37.8 ±  2.2 
Mouse DNA polymerase η  39.0 ±  2.3 
Human DNA polymerase θ  35.3 ±  2.1 
  Fish DNA Polymerase   
Cherry salmon DNA polymerase δ  32.5 ±  1.9 
  Insect DNA Polymerases   
Fruit fly DNA polymerase ʱ  34.0 ±  2.0 
Fruit fly DNA polymerase δ  36.9 ±  2.2 
Fruit fly DNA polymerase ε  36.7 ±  2.1 
  Plant DNA Polymerase   
Cauliflower DNA polymerase ʱ  >200 
  Prokaryotic DNA Polymerases   
E. coli DNA polymerase I  >200 
Taq DNA polymerase  >200 
T4 DNA polymerase  >200 
  Other DNA Metabolic Enzymes   
Calf primase of DNA polymerase ʱ  >200 
T7 RNA polymerase  >200 
T4 polynucleotide kinase  >200 
Bovine deoxyribonuclease I  >200 Int. J. Mol. Sci. 2011, 12                     
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2.3. Effect of the VK2 and VK3 Intermediates on TPA-Induced Anti-Inflammatory Activity 
In previous a pol inhibitor study, we found that there is a relationship between pol ι inhibitors and 
TPA-induced acute anti-inflammatory activity [6,19,20]. Thus, using the mouse ear inflammatory test, 
we examined the anti-inflammatory activity of the intermediates between VK2 and VK3. Application 
of TPA (0.5 κg) to the mouse ear induced edema, resulting in a 241% increase in the weight of the ear 
disk 7  h  after  application. As shown in Figure  3, pretreatment with  MK-2 and MK-1 suppressed 
inflammation, and the effect of MK-2 was stronger than that of MK-1. By contrast, MK-4, MK-3 and 
VK3 had a weak effect on the level of inflammation. Therefore, the anti-inflammatory effect of these 
compounds  correlated with their inhibitory effect on mammalian pols including pol ι, which was 
strongly inhibited by MK-2 (Figure 2). These results suggest that inhibition of pol ι activity has a 
positive correlation with the anti-inflammatory activity observed. 
Figure  3.  Anti-inflammatory  activity  of  the  VK2  and  VK3  intermediates  toward  
TPA-induced edema on mouse ear. Each compound (250 κg, gray bar; and 500 κg, black 
bar) was applied individually to one ear of a mouse, and after 30 min TPA (0.5 κg) was 
applied to both ears. Edema was evaluated after 7 h. The inhibitory effect is expressed as 
the  percentage of edema. Data are shown as the  means  ±   SE (n = 6). ** P < 0.01  and 
* P < 0.05 versus controls. 
 
2.4. Inhibitory Effect of the VK2 and VK3 Intermediates on the LPS-Induced Inflammatory Response in 
Cultured Macrophage Cells 
Next,  we  investigated  whether  the  intermediates  between  VK2  and  VK3  can  inhibit  both  the 
reduction  in  TNF-ʱ  production  and  the  nuclear  translocation  of  NF-θB  p65  induced  by  LPS 
stimulation  in  cultured  mouse  macrophage  RAW264.7  cells.  The  inflammatory  cytokine  TNF-ʱ 
activates the NF-θB signaling pathway by binding to the TNF-ʱ receptor (TNFR) and thereby initiates 
an inflammatory response, resulting in various inflammatory diseases [30]. In RAW264.7 cells, no 
compound showed cytotoxicity at 50 κM, because the LD50 values of these five compounds were 
>100 κM. As shown in Figure 4, MK-2 at 10 and 50 κM, and MK-1 at 50 κM significantly suppressed 
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the  LPS-stimulated  production  of  TNF-ʱ,  although  MK-4,  MK-3  and  VK3  displayed  a  moderate 
inhibitory effect on TNF-ʱ production. The inhibitory effects of MK-2 and MK-1 were, respectively, 
the  first  and  second  strongest  among  these  compounds.  The  effect  of  the  compounds  on  the 
suppression of LPS-evoked TNF-ʱ production showed almost the same tendency as their inhibitory 
effect on mammalian pols including pol ι. These results suggest that VK2 and VK3 intermediates, such 
as MK-2, inhibit the activities of mammalian pols, and then prevent the TNF-ʱ production in the  
LPS-induced macrophages, but not affect the cell growth. 
Figure 4. Inhibitory effects of the VK2 and VK3 intermediates on LPS-induced production 
of TNF-ʱ in the mouse macrophage cell line RAW264.7. These cells were pretreated with 
10 and 50 κM of each compound as a vehicle control (TNF-ʱ level, 52 pg/mL) for 30 min 
and then treated with 100 ng/mL LPS for 24 h (LPS-evoked TNF-ʱ level, 448 pg/mL). The 
TNF-ʱ concentration in the cell medium was measured by ELISA. The relative effect in 
the absence of the compound was taken as 100%. Data are shown as the mean ±  SE (n = 4). 
** P < 0.01 and * P < 0.05 versus controls. 
 
 
NF-θB  is  known  to  be  the  rate-controlling  factor  for  inflammatory  responses.  We  therefore 
examined  the  inhibitory  effect  of  MK-2  on  the  LPS-induced  nuclear  translocation  of  NF-θB  in 
RAW264.7 cells (Figure 5). By Western blot analysis, it was revealed that the amount of NF-θB 
nuclear translocation in RAW264.7 cells was 4.47-fold greater after LPS treatment, and that 10 κM 
MK-2 was sufficient to inhibit the LPS-stimulated nuclear translocation of NF-θB to 2.04-fold. These 
results  demonstrate  that  this  compound  can  strongly  suppress  the  nuclear  translocation  of  NF-θB 
by inhibiting  the  production  of  TNF-ʱ.  The  effects  of  MK-2  on  the  molecular  mechanism  of  
anti-inflammation will be addressed in future studies. 
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Figure 5. Inhibitory effects of MK-2 on nuclear translocation of NF-θB in RAW264.7 
cells. The cells were incubated with 10 κM MK-2 (+) or DMSO (−), as a vehicle control 
for 30 min, and then with 100 ng/mL LPS for 30 min. Nuclear proteins were prepared from 
the cells and subjected to Western blot analysis for evaluation of the nuclear translocation 
of  NF-θB  p65.  The  intensity  of  each  band  was  analyzed,  and  the  values  relative  to 
treatment without LPS (negative control, taken as 1.0-fold) are represented at the lower 
edge of the image. 
 
2.5. Inhibitory Effect of MK-2 on LPS-Induced Inflammation in Vivo 
Figure  6.  The  inhibitory  activity  of  MK-2  against  LPS-induced  inflammation  in  vivo. 
Female C57BL/6 mice were intraperitoneally injected with MK-2 at 100 mg/kg BW or 
corn oil as a vehicle control. After 30 min, the mice were intraperitoneally injected with 
LPS at 250 κg/kg BW or saline as a vehicle control. One hour after the LPS injection, the 
mice were killed, and the TNF-ʱ level in serum was measured using ELISA. Treatment 
with corn oil and LPS was a positive control (TNF-ʱ level, 1376 pg/mL), and that with 
corn oil and saline was a negative control (TNF-ʱ level, 4.2 pg/mL). Data are shown as the 
mean ±  SE (n = 5). ** P < 0.01 versus the control. 
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To  assess  in  vivo  the anti-inflammatory  effects  of  MK-2,  which  was  the  strongest  inhibitor  of 
animal  pols  and  strongest  suppressor  of  TPA-induced  inflammation  and  LPS-evoked  TNF-ʱ 
production  among  the  VK2  and  VK3  intermediates,  we  investigated  the  inhibitory  activity  of  this 
compound against LPS-induced acute inflammation (Figure 6). Treatment with 250 κg/kg BW of LPS 
considerably increased the serum TNF-ʱ level (5 ng/mL), and intraperitoneal injection of 100 mg/kg 
BW of MK-2 greatly decreased this LPS-induced TNF-ʱ production by 83.2%. Thus, the in vivo data 
obtained  in  this  mouse  study  showed  the  same  trend  as  the  data  obtained  from  cultured  mouse 
macrophage cells (Figures 4 and 5). 
3. Discussion 
VK  comprises  a  group  of  2-methyl-1,4-naphthoquinone  derivatives.  It  is  a  hydrophobic  
(i.e., insoluble in water) human vitamin. It is needed for the synthesis of proteins required for blood 
coagulation [31]. Normally, VK is produced by bacteria in the intestines, and dietary deficiency is 
extremely  rare  unless  the  intestines  are  badly  damaged.  VK  is  involved  in  the  formation  of  
calcium-binding groups in proteins [32,33]. Recently, DNA microarray was used to identify the effect 
of  VK  status  on  gene  expression  in  the  rat  liver.  The  expression  of  genes  involved  in  the  acute 
inflammation  response  was  enhanced  in  rats  fed  a  VK-deficient  diet  relative  to  the  control  and  
VK-supplemented diet groups [34]. 
VK1 and VK2 are naturally occurring types of VK. VK1 is synthesized by plants and can be found in 
such foods as spinach, broccoli, lettuce, and soybeans. VK2 is primarily produced by bacteria in the 
anterior part of the gut and the intestines. The MK-4 and MK-7 forms of VK2 are found in meat, eggs, 
dairy  and  natto.  MK-4  is  synthesized  by  animal  tissues,  other  forms  of  VK2  (mainly  MK-7)  are 
synthesized by bacteria during fermentation [35]. In natto 0% of VK is in the MK-4 form, and in 
cheese 2–7% is in this form [36]. VK3, on the other hand, is one of the many manmade versions of 
VK. Also called menadione, this yellowish, synthetic crystalline substance is converted into the active 
form of VK2 inside the animal body [37]. VK2 forms with 2–13 isoprene units, including MK-1, MK-2 
and MK-3, have been found in human and animal tissues [37]. On the other hand, Booth reported that 
though VK2 derivatives are synthesized in the intestine, intestinal MKs are not believed to be the 
primary  source  of  VK;  VK1  is  the  primary  dietary  source;  MK-4  and  MK-7  are relatively  minor 
sources in the average diet [38]. 
We have shown here that compounds that are intermediates between VK2 (MK-4) and VK3 potently 
inhibit  the  activity  of  mammalian  pols,  especially  pol  ι  (Table  1  and  Figure  2),  and  that  these 
compounds prevented the inflammatory response in vitro and in vivo (Figures 3 to 6). In particular, 
MK-2 showed the strongest of these effects among MK-1 to MK-4; therefore, the length of the side 
chain of MK-n at the 3-position of VK2 must be very important for these inhibitory activities. As 
reported previously, the phenolic compound curcumin, which is a known anti-inflammatory agent, is a 
pol-ι-specific inhibitor [6,19,20]. Intriguingly, the principle molecular target of the VK2 and VK3 
intermediates, such as MK-2, is also pol ι. 
Eukaryotic cells reportedly contain 15 pol species belonging to four families: namely, family A 
(pols γ, ζ and λ), family B (pols ʱ, δ, ε and δ), family X (pols β, ι and κ, and TdT) and family Y (pols 
ε, η and θ, and REV1) [3,4]. Among the X family of pols, pol ι seems to work in a similar way to Int. J. Mol. Sci. 2011, 12                     
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pol β [39]. Pol β is involved in the short-patch base excision repair (BER) pathway [40–43], as well as 
playing  an  essential  role  in  neural  development  [44].  Recently,  pol  ι  was  found  to  possess  
5'-deoxyribose-5-phosphate  (dRP)  lyase  activity,  but  not  apurinic/apyrimidinic  (AP)  lyase 
activity [45]. Pol ι is able to substitute for pol β during in vitro BER, suggesting that pol ι also 
participates in BER. Northern blot analysis indicated that transcripts of pol β are abundantly expressed 
in the testis, thymus and brain in rats [46], whereas pol ι is efficiently transcribed mostly in the 
testis [47]. Bertocci et al. reported that mice in which pol ι expression is knocked out are not only 
viable and fertile, but also display a normal hyper-mutation pattern [48]. 
As well as causing inflammation, TPA influences cell proliferation and has physiological effects on 
cells because it has tumor promoter activity [24]. Therefore, anti-inflammatory agents are expected to 
suppress DNA replication/repair/recombination in nuclei in relation to the action of TPA. Because 
pol ι is a repair/recombination-related pol [39], our finding—that the molecular target of VK2 and VK3 
intermediates  such  as  MK-2  is  pol  ι—is  in  good  agreement  with  this  expected  mechanism  of  
anti-inflammatory  agents.  The  detail  mechanism  by  which  MK-2  that  prevents  mammalian  pol  ι 
inhibition  could  inhibit  inflammation  is  unclear;  therefore,  to  clarify  the  exact  mechanism  of  the  
anti-inflammatory effect of MK-2, further study will be conducted. 
We have investigated the inhibitory effect of the VK2 and VK3 intermediates on the activity of 
mammalian pols, which are responsible for DNA replication leading to cell proliferation and DNA 
repair/recombination, as well as the relationship between the degree of the suppression of LPS-evoked 
TNF-ʱ production and anti-inflammatory activity. As a result, we found a positive correlation between 
the pol inhibitory activity and the anti-inflammatory activity.  
4. Experimental Section 
4.1. Materials 
VK2  (MK-4)  and  VK3  were  obtained  from  Sigma-Aldrich  (St.  Louis,  MO,  U.S.),  and  these 
structures are shown in Figure 1. Each compound was purified to more than 99% purity. Chemically 
synthesized  DNA  templates  such  as  poly(dA)  and  nucleotides  such  as  [
3H]-deoxythymidine  
5’-triphosphate  (dTTP)  (43  Ci/mmol)  were  purchased  from  GE  Healthcare  Bio-Sciences  (Little 
Chalfont,  U.K.).  The  oligo(dT)18  DNA  primer  was  customized  by  Sigma-Aldrich  Japan  K.K. 
(Hokkaido, Japan). LPS was purchased from Sigma-Aldrich. For Western blot analysis, anti-NF-θB 
p65 antibody, anti-β-actin antibody and horseradish peroxidase-conjugated anti-rabbit IgG antibody 
(i.e., secondary antibody) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.) and 
Thermo Scientific (Kanagawa, Japan), respectively. All other reagents were of analytical grade and 
purchased from Nacalai Tesque Inc. (Kyoto, Japan). 
4.2. Preparation of the VK2 and VK3 Intermediates 
The  VK2  and  VK3  derivatives  (i.e.,  MK-3,  MK-2  and  MK-1)  were  chemically  synthesized 
according to a procedure reported by Mayer and Isler with slight modification [49]. The structures of 
these compounds were confirmed by comparison of the spectral data with the reported data, and are 
shown in Figure 1. Int. J. Mol. Sci. 2011, 12                     
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4.3. Pol and Other DNA Metabolic Enzyme Assays 
Pols from mammals, a fish (cherry salmon), an insect (fruit fly) and a plant (cauliflower) were 
purified, and prokaryotic pols and other DNA metabolic enzymes, such as T7 RNA polymerase, T4 
polynucleotide kinase and bovine deoxyribonuclease I, were purchased as described in our previous 
report [50]. The activities of all pols and other DNA metabolic enzymes were measured as described in 
previous reports [50–53]. 
The components of the pol assay were poly(dA)/oligo(dT)18 and dTTP as the DNA template-primer 
and  2’-deoxyribonucleoside  5’-triphosphate  (dNTP)  substrate,  respectively.  VK2,  VK3,  and  their 
synthesized derivatives (i.e., MK-3, MK-2 and MK-1) were dissolved in dimethyl sulfoxide (DMSO) 
at various concentrations and sonicated for 30 s. The sonicated samples (4 κL) were mixed with 16 κL 
of  each  pol  enzyme  (final  amount,  0.05  units)  in  50  mM  Tris-HCl  (pH  7.5)  containing  1  mM 
dithiothreitol, 50% glycerol and 0.1 mM EDTA, and kept at 0 °C  for 10 min. These inhibitor–enzyme 
mixtures (8 κL) were added to 16 κL of each standard enzyme reaction mixture (50 mM Tris-HCl 
[pH 7.5], 1 mM dithiothreitol, 1 mM MgCl2, 15% glycerol, 10 κM poly(dA)/oligo(dT)18 and 10 κM 
[
3H]-dTTP), and incubation was carried out at 37 °C  for 60  min, except for Taq pol, which was 
incubated at 74 °C  for 60 min. Activity without the inhibitor was considered to be 100%, and the 
activity remaining at each concentration of inhibitor was determined relative to this value. One unit of 
pol  activity  was  defined  as  the  amount  of  enzyme  that  catalyzed  the  incorporation  of  1  nmol 
dNTP (dTTP) into the synthetic DNA template-primer (poly(dA)/oligo(dT)18, A/T = 2/1) in 60 min at 
37 °C  under normal reaction conditions for each enzyme (scintillation counts: approximately 1 pmol of 
incorporated radioactive nucleotides = 100 cpm) [51,52]. 
4.4. Animal Experiments 
All animal studies were performed according to the guidelines outlined in the ―Care and Use of 
Laboratory Animals‖ of Kobe University. The animals were anesthetized with pentobarbital before 
undergoing cervical dislocation. Female 8-week-old C57BL/6 mice that had been bred in-house with 
free access to food and water were used for all experiments. All of the mice were maintained under a 
12-h light/dark cycle and housed at a room temperature of 25 ° C. 
4.5. TPA-Induced Anti-Inflammatory Assay in Mouse 
The mouse inflammatory test was performed according to Gschwendt’s method [53]. In brief, an 
acetone solution of the VK2 and VK3 intermediates (250 or 500 κg in 20 κL) or 20 κL of acetone as a 
vehicle control was applied to the inner part of the mouse ear. Thirty minutes after the test compound 
was applied, a TPA solution (0.5 κg/20 κL of acetone) was applied to the same part of the ear. To the 
other ear of the same mouse, methanol, followed by TPA solution, was applied as a control. After 7 h, 
a disk (6 mm diameter) was obtained from the ear and weighed. The inhibitory effect (IE) is presented 
as a ratio of the increase in weight of the ear disks:  
IE = [(TPA only) − (tested compound plus TPA)]/[(TPA only) − (vehicle)] ×  100 
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4.6. Measurement of TNF-α Level in the Cell Culture Medium of Mouse Macrophages 
A mouse macrophage cell line, RAW264.7, was obtained from American Type Culture Collection 
(ATCC)  (Manassas,  VA,  U.S.).  The  cells  were  cultured  in  Eagle’s  Minimum  Essential  Medium 
(MEM) supplemented with 4.5 g of glucose per liter plus 10% fetal calf serum, 5 mM L-glutamine, 
50 units/mL penicillin and 50 units/mL streptomycin. The cells were cultured at 37 °C  in standard 
medium in a humidified atmosphere of 5% CO2–95% air. 
RAW264.7 cells were placed in a 12-well plate at 5 ×  10
4 cells/well and incubated for 24 h. The 
cells were pretreated with the VK2 and VK3 intermediates (final concentrations of 10 and 50 κM) for 
30 min before the addition of 100 ng/mL of LPS. After stimulation with LPS for 24 h, the cell culture 
medium was collected to measure the amount of TNF-ʱ secreted. The concentration of TNF-ʱ in the 
culture  medium  was  quantified  by  using  a  commercially  available  enzyme-linked  immunosorbent 
assay (ELISA) development system (Bay Bioscience Co., Ltd., Kobe, Japan) in accordance with the 
manufacturer’s protocol. 
4.7. Cell Treatment and Preparation of Nuclear Proteins 
RAW264.7 cells on a 6-well plate at 5 ×  10
5 cells/well were incubated with 10 κM of MK-2 or 
DMSO (1 κL/mL) as a vehicle control for 30 min, followed by treatment with 100 ng/mL of LPS for 
30 min. After treatment, cells were harvested with lysis buffer consisting of 10 mM Hepes (pH 7.9), 
10 mM  KCl,  1.5  mM  MgCl2  and  0.5  mM  DTT  containing  protease  inhibitors  (1  mM 
phenylmethylsulfonyl  fluoride  [PMSF],  5  κg/mL  of  leupeptin  and  5  κg/mL  of  aprotinin)  and 
phosphatase inhibitors (10 mM NaF and 1 mM Na3VO4) and stood on ice for 15 min with occasional 
mixing. The mixture was centrifuged at 1000 ×  g for 10 min at 4 ° C. The precipitate was suspended in 
extraction buffer consisting of 20 mM Hepes (pH 7.6), 20% (v/v) glycerol, 500 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 1.0 mM DTT and 0.1% (v/v) Nonidet P-40 containing the same protease and 
phosphatase inhibitors. The suspension was then gently mixed on a rotary device for 1 h at 4 °C  before 
being centrifuged at 15,000 ×  g for 20 min at 4 ° C. The resulting supernatant was used as a nuclear 
extract. The protein concentration was measured by using a bicinchoninic acid (BCA) assay kit in 
accordance with the manufacturer’s protocol. The nuclear proteins were subjected to Western blotting 
to evaluate the nuclear translocation of NF-θB. 
4.8. Western Blotting 
The  nuclear  proteins  (30–50  κg  of  protein)  were  boiled  in  a  quarter-volume  of  sample  buffer  
(1  M  Tris-HCl  [pH  7.5],  640  mM  2-mercaptoethanol,  0.2%  bromphenol  blue,  4%  SDS  and 
20% glycerol) and then separated on 10% SDS polyacrylamide gels. Each gel was then electroblotted 
onto a PVDF membrane. The membrane was blocked with 1% skimmed milk in Tris-buffered saline 
TBS-T  (10  mM  Tris-HCl,  100  mM  NaCl  and  0.5%  Tween-20)  and  probed  with  anti-NF-θB  p65 
antibody (1:500) and anti-β-actin antibody (1:5000), before being reacted with horseradish peroxidase 
(HRP)-conjugated  secondary  antibody  (1:5000  and  1:20,000,  respectively).  The  protein-antibody 
complex was visualized with ChemiLumiONE (Nacalai Tesque, Kyoto, Japan) and detected using an Int. J. Mol. Sci. 2011, 12                     
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Image Reader (LAS-3000 Imaging System, Fuji Photo Film, Tokyo, Japan). The intensity of each band 
was analyzed using ImageJ, which was developed at the National Institute of Health. 
4.9. In Vivo LPS-Induced Inflammatory Experiment 
Mice were intraperitoneally injected with 200 κL of MK-2 dissolved in corn oil at 100 mg/kg body 
weight (BW), or 200 κL of corn oil as a vehicle control. After 30 min, the mice were intraperitoneally 
injected with 200 κL of 250 κg/kg BW LPS dissolved in PBS or 200 κL of PBS as a vehicle control. 
After 1 h, the mice were killed, and blood samples were collected. The blood serum was separated by 
centrifugation at 15,000 ×  g for 10 min at 4 ° C, and the TNF-ʱ level in the serum was measured 
by ELISA. 
4.10. Statistical Analysis 
All data are expressed as the means ±  SE of at least three independent determinations for each 
experiment. Statistical significance between each experimental group was analyzed using Student’s  
t-test, and a level of probability of 0.01 and 0.05 was used as the criterion of significance. 
5. Conclusions 
Our study is the first to demonstrate that MK-2, which is an intermediate between VK2 (MK-4) and 
VK3, potently inhibited the activity of animal pols, especially pol ι. MK-2 also suppressed mouse ear 
inflammation stimulated by TPA and reduced NF-θB activation and TNF-ʱ production. The molecular 
mechanism that links the LPS-induced inflammatory response and anti-inflammatory activity in the 
model of TPA-induced ear edema is unknown. Because activated NF-θB has been observed in a model 
of  TPA-induced  ear  edema  [54],  the  anti-inflammatory  effects  of  MK-2  may  be,  at  least  in  part, 
dependent on the inhibition of NF-θB activation. Our study indicates that MK-2 is useful as an NF-θB 
inhibitor and may be a potent chemopreventive agent against inflammation. 
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